Show simple item record

dc.contributor.authorButt, Julia
dc.contributor.authorJenab, Mazda
dc.contributor.authorWillhauck-Fleckenstein, Martina
dc.contributor.authorMichel, Angelika
dc.contributor.authorPawlita, Michael
dc.contributor.authorKyrø, Cecilie
dc.contributor.authorTjønneland, Anne
dc.contributor.authorBoutron-Ruault, Marie-Christine
dc.contributor.authorCarbonnel, Franck
dc.contributor.authorSeveri, Gianluca
dc.contributor.authorKaaks, Rudolf
dc.contributor.authorKühn, Tilman
dc.contributor.authorBoeing, Heiner
dc.contributor.authorTrichopoulou, Antonia
dc.contributor.authorla Vecchia, Carlo
dc.contributor.authorKarakatsani, Anna
dc.contributor.authorPanico, Salvatore
dc.contributor.authorTumino, Rosario
dc.contributor.authorAgnoli, Claudia
dc.contributor.authorPalli, Domenico
dc.contributor.authorSacerdote, Carlotta
dc.contributor.authorBueno-de-Mesquita, Bas
dc.contributor.authorWeiderpass, Elisabete
dc.contributor.authorSánchez, Maria-José
dc.contributor.authorBonet Bonet, Catalina
dc.contributor.authorHuerta, JoséMaría
dc.contributor.authorArdanaz, Eva
dc.contributor.authorBradbury, Kathryn
dc.contributor.authorGunter, Marc
dc.contributor.authorMurphy, Neil
dc.contributor.authorFreisling, Heinz
dc.contributor.authorRiboli, Elio
dc.contributor.authorTsilidis, Kostas
dc.contributor.authorAune, Dagfinn
dc.contributor.authorWaterboer, Tim
dc.contributor.authorHughes, David
dc.date.accessioned2018-02-09T08:34:39Z
dc.date.available2018-02-09T08:34:39Z
dc.date.issued2018-01-29
dc.identifier.citationProspective evaluation of antibody response to Streptococcus gallolyticus and risk of colorectal cancer. 2018 Int. J. Canceren
dc.identifier.issn1097-0215
dc.identifier.pmid29377173
dc.identifier.doi10.1002/ijc.31283
dc.identifier.urihttp://hdl.handle.net/10029/621391
dc.description.abstractThe gut microbiome is increasingly implicated in colorectal cancer (CRC) development. A subgroup of patients diagnosed with CRC show high antibody responses to Streptococcus gallolyticus subspecies gallolyticus (SGG). However, it is unclear whether the association is also present pre-diagnostically. We assessed the association of antibody responses to SGG proteins in pre-diagnostic serum samples with CRC risk in a case-control study nested within a prospective cohort. Pre-diagnostic serum samples from 485 first incident CRC cases (mean time between blood draw and diagnosis 3.4 years) and 485 matched controls in the European Prospective Investigation into Nutrition and Cancer (EPIC) study were analyzed for antibody responses to eleven SGG proteins using multiplex serology. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using multivariable conditional logistic regression models. Antibody positivity for any of the eleven SGG proteins was significantly associated with CRC risk with 56% positive controls compared to 63% positive cases (OR: 1.36, 95% CI: 1.04-1.77). Positivity for two or more proteins of a previously identified SGG 6-marker panel with greater CRC-specificity was also observed among 9% of controls compared to 17% of CRC cases, corresponding to a significantly increased CRC risk (OR: 2.17, 95% CI: 1.44-3.27). In this prospective nested case-control study we observed a positive association between antibody responses to SGG and CRC development in serum samples taken pre-diagnostically. Further work is required to establish the possibly etiological significance of these observations and whether SGG serology may be applicable for CRC risk stratification. This article is protected by copyright. All rights reserved.
dc.language.isoenen
dc.rightsinfo:eu-repo/semantics/closedAccessen
dc.titleProspective evaluation of antibody response to Streptococcus gallolyticus and risk of colorectal cancer.en
dc.typeArticleen
dc.identifier.journalInt J cancer 2018; advance online publication (ahead of print)en
html.description.abstractThe gut microbiome is increasingly implicated in colorectal cancer (CRC) development. A subgroup of patients diagnosed with CRC show high antibody responses to Streptococcus gallolyticus subspecies gallolyticus (SGG). However, it is unclear whether the association is also present pre-diagnostically. We assessed the association of antibody responses to SGG proteins in pre-diagnostic serum samples with CRC risk in a case-control study nested within a prospective cohort. Pre-diagnostic serum samples from 485 first incident CRC cases (mean time between blood draw and diagnosis 3.4 years) and 485 matched controls in the European Prospective Investigation into Nutrition and Cancer (EPIC) study were analyzed for antibody responses to eleven SGG proteins using multiplex serology. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using multivariable conditional logistic regression models. Antibody positivity for any of the eleven SGG proteins was significantly associated with CRC risk with 56% positive controls compared to 63% positive cases (OR: 1.36, 95% CI: 1.04-1.77). Positivity for two or more proteins of a previously identified SGG 6-marker panel with greater CRC-specificity was also observed among 9% of controls compared to 17% of CRC cases, corresponding to a significantly increased CRC risk (OR: 2.17, 95% CI: 1.44-3.27). In this prospective nested case-control study we observed a positive association between antibody responses to SGG and CRC development in serum samples taken pre-diagnostically. Further work is required to establish the possibly etiological significance of these observations and whether SGG serology may be applicable for CRC risk stratification. This article is protected by copyright. All rights reserved.


This item appears in the following Collection(s)

Show simple item record